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Summary
The tumor suppressor STAT1 is considered a key regulator of the surveillance of developing tumors. Here, we describe an
unexpected tumor-promoting role for STAT1 in leukemia.STAT12/2mice are partially protected from leukemia development,
and STAT12/2 tumor cells induce leukemia in RAG22/2 and immunocompetent mice with increased latency. The low MHC
class I protein levels of STAT12/2 tumor cells enable efficient NK cell lysis and account for the enhanced tumor clearance.
Strikingly,STAT12/2 tumor cells acquire increasedMHCclass I expressionupon leukemiaprogression. Thesefindingsdefine
STAT1 as a tumor promoter in leukemia development. Furthermore, we describe the upregulation of MHC class I expression
as a general mechanism that allows for the escape of hematopoietic malignancies from immune surveillance.Introduction
The JAK (Janus kinase)-STAT (signal transducer and activator of
transcription) signaling pathway mediates a variety of important
cellular functions in the hematopoietic system. Ligand binding
on the cognate receptor leads to activation of receptor-associ-
ated JAKs, which subsequently tyrosine-phosphorylate and ac-
tivate STAT proteins. After formation of dimers, STAT proteins
translocate to the nucleus, where they induce or modulate
expression of target genes (Bromberg and Darnell, 2000; Levy
and Darnell, 2002).
Targeted deletion was instrumental in clarifying the physiolog-
ical role of STAT1 in vivo (Durbin et al., 1996; Meraz et al., 1996).
STAT12/2mice are viable and fertile but are more susceptible to
viral and bacterial infections. This phenotype was attributed to a
lack of IFN-g signaling. Originally, the development and distribu-
tion of lymphocytes seemed unaffected in STAT12/2 animals.
Later reports, however, revealed defects in the maturation of T
lymphocytes (Fallarino and Gajewski, 1999; Lee et al., 2000b;
Refaeli et al., 2002) and documented an impaired cytolytic capac-
ity of NK cells (Lee et al., 2000a). STAT12/2 T cells proliferated
faster and showed a reduced propensity to undergo apoptosis
due to diminished expression levels of caspase 1, 8, and 11. Re-
cently, an increased susceptibility to autoimmunediseasewas re-
ported in STAT12/2 mice due to an impaired function of CD4+/
CD25+ regulatory T suppressor cells (Nishibori et al., 2004).CANCER CELL 10, 77–87, JULY 2006 ª2006 ELSEVIER INC. DOI 10.101STAT12/2mice have also been shown to be tumor prone, and
STAT1 was therefore classified as a tumor suppressor (Badg-
well et al., 2004; Kaplan et al., 1998; Lesinski et al., 2003; Shan-
karan et al., 2001). Onemechanism bywhich STAT1 suppresses
tumor formation is its key role as a transcription factor down-
stream of type I and type II interferons (IFNs). IFN-a is widely
used for the treatment of metastatic melanoma and for certain
forms of leukemia, where it can induce disease regression.
IFN-g is a key component of tumor surveillance and protects
the host against spontaneously arising tumors (Dalton et al.,
1993; Sexl et al., 2003; Street et al., 2002). Accordingly, sponta-
neously arising and metylcholanthrene (MCA)-induced tumors
evolve faster inmice deficient for components of IFN-g signaling
than in wild-type controls (Kaplan et al., 1998). Similarly, sponta-
neous tumor development is increased in IFN-g- and perforin-
deficient mice, which develop lymphomas and/or sarcomas
with a higher frequency than wild-type animals (Smyth et al.,
2000; Street et al., 2002). These findings support a model where
IFN-g tightly collaborates with lymphocytes to protect the host
from tumor development; as predicted from this concept, tu-
mors arising in immunocompromised RAG22/2 mice are easily
rejected when transplanted into (syngenic) immunocompetent
wild-type hosts (Dunn et al., 2002; Dunn et al., 2004; Ikeda
et al., 2002; Shankaran et al., 2001).
Still, the mechanism of tumor editing is only poorly under-
stood. A very recent report implies a so far underestimatedS I G N I F I C A N C E
So far, STAT1 was classified as a tumor suppressor, and STAT12/2 mice were shown to be prone to develop solid tumors. The tumor-
suppressing effect of STAT1 was attributed to its role as a key transcription factor downstream of IFN signaling. We now show that
STAT1 can accelerate the development of hematopoietic tumors independently of IFN signaling. Moreover, we demonstrate that
the upregulation of MHC class I molecules represents a general mechanism to escape tumor surveillance and that low MHC class I
expression might be beneficial for leukemia patients. Our study may therefore redirect immune-therapeutic considerations. The loss
of STAT1 is observed in humanmalignancies, and anticancer drugs like fludarabine are knownmodulators of STAT1 protein expression.6/j.ccr.2006.05.025 77
A R T I C L Erole of the innate immune system for tumor surveillance (Street
et al., 2004). Herein, it is shown that rejection of spontaneous
B cell lymphoma arising in immunocompromised mice (b2-mi-
croglobulin- or perforin-deficient) was mediated by NK and gd
T cells. More importantly, depletion of either CD4+, CD8+, or
both populations from wild-type mice did not prevent tumor
rejection.
We explored the contribution of the innate immune system to
tumor evolution by investigating two types of hematological
cancers: B-lymphoid malignancies induced by the v-abl-onco-
gene and myeloproliferative disorders (MPDs) caused by the
TEL/JAK2 oncogene. Bothmurinemodels are relevant to clinical
disease in people because the oncogenes that drive tumor de-
velopment have a human counterpart. The oncogenic proper-
ties of v-abl are based on a fusion of the retroviral gag gene
with a C-terminal portion of the c-abl gene. The resulting fusion
product codes for a constitutively active tyrosine kinase located
in the cytoplasm (Rosenberg and Witte, 1988; Witte, 1986).
Transformation with a replication-deficient retrovirus encoding
v-abl transforms fibroblasts and B-lymphoid precursors in vitro
and leads to development of primary B cell leukemia and lym-
phoma in vivo (Abelson and Rabstein, 1970; Palumbo et al.,
1990). The inflicted disease develops slowly and allows the
immune system to take corrective actions.
MPDs are clonal hematopoietic stem cell malignancies
(Spivak, 2004). The TEL/JAK2 oncogene was initially isolated
from T cell childhood leukemia and encodes an ETS transcrip-
tion factor family member fused to the catalytic domain of
JAK2 (Lacronique et al., 1997; Peeters et al., 1997). The fusion
protein is a constitutively active tyrosine kinase. Transformed
bonemarrow cells that express TEL-JAK2 induceMPD and lym-
phoblastic lymphoma (LBL) after transplantation into lethally
irradiated wild-type mice (Carron et al., 2000; Schwaller et al.,
1998). Very recently, a single-nucleotide mutation in the pseu-
dokinase domain of JAK2 (V617F) was found in w75%–90%
of polycythemia vera (PV) patients and in other MPDs (James
et al., 2005; Kralovics et al., 2005; Levine et al., 2005). Again,
this mutation leads to the constitutive activation of JAK2. These
observations highlight the similarity between the murine model
and the manifestation of the disease in people.
Here, we demonstrate, to our knowledge, a previously unde-
scribed role of STAT1 for the development of hematopoietic ma-
lignancies. STAT1 promotes leukemia development by main-
taining high MHC class I expression. Leukemic cells that
express low MHC class I levels need to upregulate MHC class
I levels to allow for development of leukemia in vivo. Our findings
were recapitulated in two independent experimental systems,
i.e., V-abl-induced and TEL-JAK2-induced tumors that arise
from distinct progenitor cells. STAT1-mediated regulation of
MHC class I is of general relevance to understand the mecha-
nisms that underlie the evolution of tumor cells under the pres-
sure of the immune system.
Results
STAT12/2 B cell precursors are susceptible
to transformation with v-abl
The transforming activity of v-abl includes the ability to abrogate
growth factor requirements of B cell progenitors (Palumbo et al.,
1990). Lymphocytes from STAT12/2mice have previously been
shown to undergo increased proliferation and have prolonged78survival in vitro (Lee et al., 2000b). We therefore assessed the
consequences of STAT1 deficiency on growth factor-indepen-
dent proliferation of fetal liver cells after oncogenic transforma-
tion. STAT12/2 fetal liver cells were transformed with v-ablmore
efficiently and gave rise to increased numbers of growth factor-
independent CD43+/CD19+/B220+ (pro-B) cell colonies (Figures
S1A–S1C in the Supplemental Data available with this article
online). The size of colonies in methylcellulose did not vary
between STAT1+/2 and STAT12/2 cells, indicating that trans-
formed STAT12/2 cells did not have any proliferative advantage
(Figure S1D). Because STAT1 has recently been implicated in
apoptosis (Agrawal et al., 2002; Lee et al., 2000b), we analyzed
cell death in response to serum starvation and UV irradiation.
Three independently derived cell lines from STAT1+/2 and
STAT12/2 fetal liver cell suspensions were analyzed and dis-
played no significant differences (p = 0.26 in Figure S2A and
p = 0.6 in Figure S2B). In some cell types, STAT1 was also shown
to inhibit cell proliferation by increasing the levels of cyclin-
dependent kinase inhibitors p21 and p27 (Lee et al., 2000b;
Yu and Jove, 2004). As already indicated by the equal size of
the transformed colonies, v-abl-transformed STAT1+/2 and
STAT12/2 pro-B cells did not vary in their proliferative capacity
(p = 0.49; Figure S2C). Immunoblots for cell cycle components
confirmed equal protein expression of cyclin D2, cyclin E, cyclin
A, and the cell cycle inhibitors p53, p16, p19, p21, and p27 in
STAT1+/2 andSTAT12/2 cell lines (Figures S2D and S2E). Taken
together, our data lead us to conclude that STAT1 counteracts
the initial transformation process but has no appreciable impact
on cell proliferation or survival of transformed pro-B cells.
Lack of STAT1 decreases leukemia formation
in immunodeficient mice
To address the role of STAT1 for the formation of B-lymphoid
leukemia in vivo, six independently derived v-abl-transformed
STAT1+/2 and six STAT12/2 cell lines were injected intrave-
nously into RAG22/2 mice. Three different concentrations of
each transformed cell line were injected (106, 105, and 5 3 104
cells/mouse; Figures 1A–1C). All RAG22/2 mice that had re-
ceived STAT1+/2 leukemic cells succumbed to the disease
and displayed the classical signs of leukemia: high numbers of
B-lymphoid cells were detected in the peripheral blood, and leu-
kemic cells infiltrated liver, spleen, and bone marrow (data not
shown). The latency of disease correlated with the number of
cells injected. Within 22 days, 106 cells induced leukemia; 105
cells induced leukemiawithin 34 days, and 53 104 cells induced
leukemia within 46 days.
The correlation between injected cell number and disease
latency was more evident when transformed STAT12/2 pro-B
cells were injected. Whereas 106 STAT12/2 cells induced leuke-
mia with the same latency as STAT1+/2 cells (p = 0.76), differ-
ences emerged upon injection of 105 cells (Figure 1B). Most in-
terestingly, some RAG22/2 mice even survived the challenge
with STAT12/2 leukemic cells and remained disease-free for
more than 12 months (Figures 1B and 1C). Injection of 105
STAT12/2 cells resulted in disease onset in 80% of the injected
RAG22/2mice with a disease latency of 47 days (p = 0.04). This
difference was even more pronounced when cell numbers were
lowered to 53 104 cells (Figure 1C). In this case, 40% of the in-
jectedRAG22/2mice remained healthy formore than 10months
(p = 0.03). Mice that had developed leukemia upon injection of
STAT12/2 cells showed a profound decrease in infiltration ofCANCER CELL JULY 2006
A R T I C L Espleen and liver compared to mice that had received STAT1+/2
cells (Figure 1D and data not shown). The bone marrow repre-
sents the initial site of disease development. To test whether
STAT12/2 cells have difficulties in homing to the bone marrow,
we labeled leukemic cells with the fluorescent dye CFSE and in-
jected these into RAG22/2 as well as into wild-type recipient
mice. The fluorescence intensity decreases with each cell divi-
sion, since CFSE is equally distributed between the daughter
Figure 1. Lack of STAT1 decreases leukemia formation in RAG22/2 mice
A–C: In total, six individual cell lines (STAT1+/2and STAT12/2) were injected at
different doses into RAG22/2 mice. Leukemia development was observed
for more than 250 days. Three different cell numbers (106 cells [A], 105 cells
[B], and 5 3 104 cells [C]) of each genotype were injected into RAG22/2
mice (n = 6 for each genotype/experiment in A and B; n = 8 for each geno-
type in C).
D: Hematoxylin/eosin-stained histological sections of infiltrated livers from
RAG22/2 mice, which had received STAT1+/2 (left panel) or STAT12/2 cell
lines (right panel; magnification: 3100). Two representative examples are
depicted for each genotype.
E: Short-term proliferation of CFSE-labeled STAT1+/2 or STAT12/2 leukemic
cells was assessed in vitro (left panel), and wild-type BALB/c and RAG22/2
mice were assessed 4 days after injection (right panel).CANCER CELL JULY 2006cells. Four days after the injection of tumor cells, the bone mar-
row was analyzed for the presence of CFSE+ cells. As depicted
in Figure 1E,STAT1+/2 andSTAT12/2 cells were present at com-
parable numbers inRAG22/2 (0.099%6 0.005%and 0.111%6
0.006%; p = 0.8) and in wild-type mice (0.111% 6 0.019% and
0.104% 6 0.004%; p = 0.75). Importantly, the fluorescence in-
tensity that was recorded ex vivo did not differ in STAT1+/2
and STAT12/2 cells. This observation confirmed again that the
proliferative capacity of STAT12/2 cells was not affected.
STAT12/2 tumor cells express low levels of MHC class I
Tumor development is a permanent battle of the evolving tumor
and the immune system. It is evident that the injection of low
numbers of tumor cells allows the immune system to take cor-
rective action, whereas high cell numbers are likely to overrun
the immunological defense mechanisms. Therefore, we rea-
soned that tumor surveillance accounted for the increase in sur-
vival of RAG22/2mice. RAG22/2mice lack functional T/B, NKT,
and gdT cells and rely on NK cells for tumor surveillance (Shinkai
et al., 1992). The presence of MHC class I molecules is one of
the central mechanisms that allow NK cells to recognize their
targets. Cells bearing low levels of MHC class I are readily rec-
ognized as ‘‘non-self’’ and eliminated by NK-mediated cytotox-
icity (Cerwenka and Lanier, 2001; Colucci et al., 2003; Karre
et al., 1986; Lee et al., 1999). Hence, we tested the expression
levels of MHC class I (H-2Dd) on the surface of six individual
STAT1+/2 and six individual STAT12/2 cell lines. These in vitro-
transformed STAT12/2 pro-B cells consistently showed drasti-
cally reduced MHC class I surface expression compared to
in vitro-transformed STAT1+/2 cells (Figure 2A). In contrast to
transformed STAT12/2 cells, v-abl-transformed IFN-g2/2 pro-
B cells did not show any alterations in MHC class I surface
expression, indicating that the decreased expression is a cell-
autonomous feature of transformed STAT12/2 B-lymphoid cells
and independent of an autocrine IFN loop. In addition, we incu-
bated freshly prepared fetal liver cells with high concentrations
of v-abl retrovirus. Infection with the retrovirus did not enhance
the MHC class I expression (Figure 2B).
Thus, the findings summarized are consistent with the inter-
pretation that neither the retroviral infection nor an autocrine
IFN-g loop does per se elevate MHC class I expression and
that changes in MHC class I expression reflected cell autono-
mous properties of the tumor cells. The regulation of MHC class
I by STAT1 has also been documented by others (Kamiya et al.,
2004; Lee et al., 1999; Lieberman et al., 2004). However, the
experiments did not prove that the NK cell compartment was
required to account for the differences in outcome observed in
animals challenged with STAT1-expressing and STAT1-defi-
cient cells (Figures 1A–1C). To address this issue, we injected
STAT1+/2 and STAT12/2 tumor cells at low numbers (5 3 104
cells each) intoRAG22/2gc2/2mice, which lack all effector cells
of the immune system, including NK cells (Goldman et al., 1998).
We did not observe any differences in latency, survival, or dis-
ease morphology in livers, spleens, lymph nodes, or bone mar-
row from mice bearing either STAT1+/2 or STAT12/2 leukemia
(Figure 2C; p = not significant and data not shown).
Raising MHC class I levels restores the leukemogenicity
of STAT12/2 cells
We reasoned that the decreased incidence and increased
latency of leukemia induced by STAT12/2 cells is a direct79
A R T I C L Econsequence of low expression of MHC class I, which allows for
more efficient NK cell recognition. To test this, we overex-
pressed MHC class I (H-2Dd-IRES-GFP) in STAT12/2 leukemic
cells (Figure 3A). As expected, STAT12/2 cells overexpressing
H-2Dd could not be lysed efficiently by NK cells in an in vitro cy-
totoxicity assay (Figure 3B; p < 0.001 for STAT12/2 versus
STAT1+/2 and STAT12/2 versus STAT12/2 +MHC I; p = not sig-
nificant for STAT1+/2 versus STAT12/2 + MHC I). We selected
one independently derived STAT12/2 cell line that expressed
levels of H-2Dd comparable to STAT1+/2 control cells. Forced
expression of MHC class I did not alter cell proliferation or the
response to proapoptotic stimuli (data not shown). Differences
in survival are most readily detected if RAG22/2 mice are chal-
lengedwith a low burden of tumor cells (Figure 1C).We therefore
lowered the number of injected cells to 3 3 104 cells/mouse.
This burden of the parental STAT12/2 cell line was unable to
Figure 2. v-abl-transformed STAT12/2 cell lines express low levels of MHC
class I
A: v-abl-transformed STAT1+/2 and STAT12/2 as well as IFN-g+/+ and IFN-g2/2
cell lines were stained with isotype control (left panels) and a-H-2Dd (right
panels).
B: STAT1+/2 and STAT12/2 fetal liver cells were prepared and stained with
antibodies against CD19 and MHC class I (H-2Dd). Prior to staining, the cells
were infected with v-abl retrovirus (upper panel) or stimulated with IFN-g
(10 ng/ml, lower panel) for 24 hr.
C: Kaplan-Meier plot representing the survival of RAG22/2gc2/2 mice (n = 5
each) injected with either STAT1+/2 or STAT12/2 cells (v-abl-transformed, 53
104 cells/mouse).80inflict leukemia in RAG22/2mice. In contrast, the cell line stably
expressing MHC class I induced disease in 5/6 RAG22/2 mice,
with a mean survival of 61.6 days. Transformed STAT1+/2 cells
were included as controls and also induced disease in 5/6 mice
with a mean survival of 27.1 days (Figure 3C; p = 0.001). A sec-
ond independently performed experiment using the same cell
lines was repeated in STAT12/2mice and confirmed this obser-
vation (Figure S3; p = 0.001). Analysis of the diseased animals
revealed that the bone marrow, spleen, and blood were densely
infiltrated with leukemic cells expressing high levels of H-2Dd,
and these B cells were also positive for GFP (Figure 3D). These
experiments defineMHC class I expression on leukemic cells as
a key determinant for the NK-mediated tumor surveillance.
Unrejected STAT12/2 leukemic cells have an ‘‘edited’’
phenotype
Tumor cells can evade the selective pressure of the adaptive
immune system by downregulating MHC class I expression on
their cell surface (Garcia-Lora et al., 2003; Karre et al., 1986;
Figure 3. Overexpression of MHC class I in STAT12/2 cell lines increases the
incidence and shortens the latency of leukemia
A: pMSCV-H-2Dd-IRESeGFP was transduced into a STAT12/2 cell line, and its
expression was compared to the parental STAT12/2 and a STAT1+/2 cell line
infected with the empty retroviral construct by flow cytometry. The mean
fluorescence intensity (MFI) of MHC class I is indicated in the panel. In paral-
lel, cytotoxicity assays (B) were performed using wild-type NK cells as effec-
tors. Data represent mean 6 SD. Subsequently, cell lines were injected into
RAG22/2 mice (n = 6 for each group), and leukemia development was ob-
served over a time period of 300 days (C). Flow cytometry analysis of mice
that had developed leukemia showed an infiltration of bone marrow
(BM), spleen, and blood with tumor cells that were GFP+ and expressed
high levels of MHC class I (D).CANCER CELL JULY 2006
A R T I C L EFigure 4. MHC class I upregulation in STAT12/2 tumor cells occurs as a conse-
quence of immunoediting
A and B: V-abl-transformed STAT12/2 (A) and STAT1+/2 (B) cell lines (5 3 104
cells/mouse) were injected into six RAG22/2 mice each. Tumor develop-
ment was observed for 6 months. Expression of CD19 and MHC class I was
assessed in the cell lines by flow cytometry prior to injection (left panels),
as well as in bone marrow (BM), spleen, and blood of mice that had devel-
oped leukemia (right panels). Two representative examples for STAT12/2-
induced leukemia (A) and one representative example for STAT1+/2-induced
leukemia (B) are depicted.
C: Cytotoxicity assays were performed using wild-type NK cells and two
ex vivo derived STAT12/2 cell lines with high MHC class I expression,
and STAT1+/2 and STAT12/2 cell lines as control. Data represent mean
6 SD.
D: Analysis of transcriptional expression of IRF-1 and b2-microglobulin (b2m)
genes by semiquantitative RT-PCR. One representative STAT1+/2 and
STAT12/2 cell line and their corresponding tumor-derived cell lines were an-
alyzed for the expression of IRF-1 and b2m mRNA (middle and right panel).
As a control for expression of IRF-1 and b2m, cells were stimulated withCANCER CELL JULY 2006Mocikat et al., 2003; Smyth et al., 2002). We speculated that the
opposite might occur in tumors that are predominantly eradi-
cated by NK cells: tumors may escape the immune system by
upregulating MHC class I molecules on their cell surface. This
conjecture would also explain why, in RAG22/2 mice, STAT12/2
cells are not entirely cleared by the immune system and eventu-
ally succeed in inducing leukemia.
This hypothesis was verified by using the following approach:
four individualSTAT12/2 and three individualSTAT1+/2 cell lines
(105 cells each) were injected into RAG22/2 mice (n = 12 each).
The MHC class I expression of these cells was determined prior
to injection and compared to the MHC class I levels on leukemic
cells arising in bone marrow, spleen, and peripheral blood from
diseased RAG22/2 mice.
As depicted in Figure 4A, in all mice (n = 12) that had received
STAT12/2 transformed cells, a cell population emerged that
was CD19+ and that expressed increased levels of MHC class
I. This cell population was detected in peripheral blood, bone
marrow, and spleen of the diseasedRAG22/2mice. In vitro cyto-
toxicity assays confirmed that the cells expressing high levels
of MHC class I were either not killed or killed in fewer numbers
by purified NK cells when compared to the parental cell line
(Figure 4C, p < 0.001 for STAT12/2 versus STAT1+/2, STAT12/2
versus STAT12/2 MHC Ihigh line 1, and STAT12/2 versus
STAT12/2 MHC Ihigh line 2; p = 0.01 for STAT1+/2 versus
STAT12/2MHC Ihigh line 1; p = not significant for STAT1+/2 ver-
sus STAT12/2 MHC Ihigh line 2). In contrast, none of the trans-
planted RAG22/2 mice (n = 12) that had received STAT1+/2 tu-
mor cells displayed this phenomenon (Figure 4B). Most
importantly, if the tumor-derived STAT12/2 cells were propa-
gated in vitro, they retained the expression of high levels of
MHC class I even after long cultivation periods (>2 months;
Figure 4D). This allowed us to explore the underlying molecular
mechanisms, which resulted in an increased MHC class I ex-
pression. We concentrated on the proposed regulatory factors
implicated in the regulation of gene expression of theMHC class
I protein complex and on the processing mechanism leading to
their surface expression (Gobin et al., 2003; Hobart et al., 1997;
Lee et al., 1999). When compared to their parental cell lines,
MHC class Ihigh cells consistently expressed higher levels of
the transcription factor IRF-1 and b2-microglobulin (b2m) (Fig-
ure 4D). In contrast, we did not observe any alterations in the
levels of LMP-2, LMP-7, TAP-1, CIITA, or SOCS-1 mRNAs
(data not shown).
Taken together, these experiments prove that selective pres-
sure of the innate immune system enables the upregulation of
MHC class I expression by increasing the IRF-1 and b2-micro-
globulin mRNA expression. The importance of this phenomenon
is underlined by the fact that it occurred in all (12/12) RAG22/2
mice investigated.
STAT12/2 mice are partially protected from leukemia
formation
Previous experiments revealed a reduced cytotoxic capacity of
STAT12/2 NK cells (Lee et al., 2000a). It was therefore question-
able whether the impaired cytotoxic ability ofSTAT12/2NK cells
10 ng/ml IFN-g for 2 hr (left panel). MHC class Ilow corresponds to the in vitro
derived STAT12/2 parental cell line, whereas MHC class Ihigh corresponds to
the tumor-derived STAT12/2 cell line.81
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icated tumor cells arising in STAT12/2 mice (which bear
STAT12/2NKcells). These questionswere addressed by the fol-
lowing experiments: we first confirmed thatSTAT12/2 cells have
an impaired cytotoxic capacity by using purified and in vitro am-
plified NK cells as effectors and YAC-1 cells as target cells (data
not shown). YAC-1 cells represent optimal target cells because
of their low MHC class I levels. However, they may behave
differently from transformed B-lymphoid cells. Therefore, we
used v-abl-transformed cell lines as targets. STAT1+/2 and
STAT12/2 NK cells were tested for their ability to lyse STAT1+/2
or STAT12/2 tumor cells in any possible combination. STAT1+/2
tumor cells were not killed by NK cells, irrespective of their
genotype (Figure 5A; p < 0.001 for STAT1+/2 NK cells killing
STAT12/2 versus STAT1+/2 NK cells killing STAT1+/2 targets
and for STAT12/2 NK cells killing STAT12/2 versus STAT12/2
NK cells killing STAT1+/2 targets; p = not significant for
STAT1+/2 targets versus STAT1+/2 or STAT12/2 NK cells). In
contrast, STAT12/2 tumor cells were efficiently recognized
and lysed by NK cells of both genotypes. STAT1+/2 NK cells
efficiently eradicated STAT12/2 leukemic cells, but they were
unable to eradicate leukemic cells of their own genotype. How-
ever, in spite of their reduced cytotoxic capacity, STAT12/2 NK
cells were still able to recognize and eliminate STAT12/2 tumor
cell targets (Figure 5A).
Infection of newborn BALB/c mice with a retrovirus encoding
for v-abl results in onset of B-lymphoid leukemia/lymphoma
within weeks. The inflicted disease is mono- or oligoclonal and
evolves slowly, allowing the immune system to take corrective
action. To ask whether the absence of STAT1 in the tumor or
the absence of STAT1 in NK cells contributed to leukemia devel-
opment in vivo, we performed infections in wild-type and
STAT12/2 mice. To ensure appropriate littermate controls,
STAT1+/2 and STAT12/2 mice were intercrossed and the off-
spring injected with retrovirus within 24 hr after birth. All 11
STAT1+/2 mice (100%) died from leukemia within 5 weeks,
whereas 6/28 (21%) of the injected STAT12/2 mice remained
healthy and disease-free for more than 8 months despite the
oncogenic challenge (Figure 5B; p < 0.001). Twenty-two out of
twenty-eight STAT12/2 animals developed leukemia, and in
these animals the disease latency was increased and the signs
of disease were mitigated (decreased white blood cell counts,
reduced tumor cell infiltrations in liver, spleen, and bone mar-
row) compared to those in STAT1+/2 littermate controls
(Figure 5B).
Our model predicts that the leukemia that eventually arises in
STAT12/2 mice is accompanied by an upregulation of MHC
class I during the development of disease. As expected, MHC
class I surface expression on leukemic cells infiltrating bone
marrow, spleen, and forming tumors was highly increased com-
pared to nonleukemic (CD19-negative) cells of the same tissue
(Figure 5D).
STAT12/2 animals have been repeatedly used to study the ef-
fects of IFN-g in tumor surveillance (Kaplan et al., 1998; Shan-
karan et al., 2001). However, transformed IFN-g2/2 and
STAT12/2 B-lymphoid cells differ substantially in MHC class I
expression. Thus, infection of newborn IFN-g2/2 mice with v-
abl retrovirus is predicted to result in an opposite phenotype,
that is, aggravated disease. As depicted in Figure 5E, 40% of
the wild-type control C57BL/6 mice remained disease-free
(this is the expected result for this genetic background), whereas82100% of the IFN-g2/2mice succumbed to a rapidly progressing
leukemia within 4 weeks (p < 0.0001). We want to stress that the
disease latency of STAT12/2 and IFN-g2/2 animals cannot be
directly compared because the animals differ in their genetic
background (see Experimental Procedures). These experiments
confirm the important role of IFN-g for tumor surveillance. More
importantly, we stress that STAT1 and IFN-g deficiency cannot
be superimposed in the case of tumors predominantly eradi-
cated by NK cells.
Figure 5. Decreased leukemia formation in STAT12/2 mice after V-abl
challenge
A: Cytotoxicity assays were performed with purified NK cells from STAT1+/2
and STAT12/2 mice as effector cells and STAT1+/2 and STAT12/2 v-abl-trans-
formed cell lines as target population. Data represent mean 6 SD.
B: Kaplan-Meier plot indicating survival of the littermate progeny from
a STAT1+/2 3 STAT12/2 intercross infected with v-abl retrovirus. Survivors
were followed up over a period of 8 months for leukemia development
(n = 11 for STAT1+/2 and n = 28 for STAT12/2).
C: Representative hematoxylin/eosin-stained blood smears from three mice
of each group are shown (magnification: 3100).
D: Expression of CD19 and MHC class I was assessed by flow cytometry
in bone marrow (BM), spleen, and a tumor from one representative
STAT12/2 mouse, which rapidly developed leukemia. An upregulation is ob-
served for MHC class I in the leukemic cells compared to nonleukemic cells.
E: Kaplan-Meier plot of IFN-g+/+ and IFN-g2/2mice after v-abl retrovirus chal-
lenge (n = 13 for IFN-g+/+ and n = 11 for IFN-g2/2).CANCER CELL JULY 2006
A R T I C L EFigure 6. Low tumorigenicity of STAT12/2 leuke-
mic cells in immunocompetent mice
A and B: Kaplan-Meier plots indicating survival of
immunocompetent BALB/c mice bearing either
STAT1+/2 or STAT12/2 leukemia. Two different
cell numbers (33 106 [A] cells and 33 105 [B] cells
of each genotype) were injected into wild-type
BALB/c mice (n = 10 per genotype and cell
amount used).
C: Flow-cytometric analysis of CD19 and MHC
class I expression in the cell lines used for injection
(left panel) and in the bone marrow (BM) from
three representative mice each that had devel-
oped leukemia upon injection of STAT1+/2 and
STAT12/2 cells (numbers on top of the scatter
plot identify the individual mouse).
D: Kaplan-Meier plots of immunocompetent
BALB/c mice injected with either STAT1+/2 or
STAT12/2 leukemic cells after depletion of NK
cells with a-asialo GM1.Loss of STAT1 delays disease progression
in immunocompetent animals
and in TEL-JAK2 leukemic mice
Our data show the central role of STAT1 during leukemia devel-
opment in maintaining high expression levels of MHC class I.
However, both RAG22/2 and STAT12/2 mice do have an im-
paired immune system. We therefore investigated disease pro-
gression inflicted by STAT12/2 and STAT1+/2 leukemic cells in
immunocompetent hosts (BALB/c animals). This experimental
setup mimics the situation in human patients, where a loss of
STAT1 can be found in leukemic cells (Irish et al., 2004; Landolfo
et al., 2000; Sun et al., 1998).
We transplanted STAT1+/+ or STAT12/2 v-abl-transformed
cells at different numbers into syngeneic immunocompetent
BALB/c (wild-type) mice. As depicted in Figures 6A and 6B,
wild-type mice that had received STAT12/2 tumor cells showed
an increased latency of disease—irrespective of the injected cell
number (p < 0.01 and p < 0.005). STAT12/2 leukemic cells were
isolated from the diseased mice and again showed a significant
increase in MHC class I expression (Figure 6C). Depletion of NK
cells by repeated injections of a-asialo GM1 antibody in wild-
type mice abolished the differences in disease latency (Fig-
ure 6D; p = not significant). Together, these experiments prove
that STAT1 also plays a crucial role as a tumor promoter in the
context of an intact immune system by interfering with NK
cell-mediated tumor lysis.CANCER CELL JULY 2006V-abl-induced B-lymphoid leukemia may represent a specific
challenge to the immune system, and the observations summa-
rized above may therefore be of limited importance. In order to
document that they reflect a more general mechanism of tumor
escape in hematopoietic malignancies, we chose MPD induced
by constitutively active JAK2 as a second independent leukemia
model. Bone marrow cells of wild-type and STAT12/2 BALB/c
mice were infected with a retrovirus encoding the TEL/JAK2
fusion protein (Schwaller et al., 1998). Infection rates were con-
trolled by FACS and were found to be comparable (around 5%)
at the time point of injection. The cells were transplanted into five
wild-type recipients each. All mice were analyzed 3months after
injection. At this time point, the first mice that had been injected
with STAT1+/2 bone marrow were obviously sick and displayed
elevated red blood cell counts accompanied by thrombo-
cytosis, granulocytosis, and splenomegaly (James et al., 2005;
Kralovics et al., 2005; Levine et al., 2005). The hematocrit
values as well as the numbers of granulocytes were significantly
lower in mice that had been injected with STAT1-deficient cells
than in those injected with STAT1-expressing cells (Figure 7A;
p < 0.001 and data not shown). MPD is characterized by aber-
rations in early hematopoietic progenitors. As indicated in the
upper panels of Figure 7B, erythroid precursor cell numbers
(P2/P3/P4/P5 regions) were elevated 3-fold in mice that had
been injected with TEL/JAK2-infected STAT1+/2 bone marrow
compared to TEL/JAK2-infected STAT12/2 bone marrow83
A R T I C L E(20.5% 6 1.1% versus 8.2% 6 0.4%, respectively; p < 0.01).
This difference was even more pronounced with respect to the
amount of GFP+ cells. Whereas 31.4%6 5.1% of erythroid pre-
cursor cells were GFP+ in mice injected with wild-type TEL/
JAK2-infected cells, only 3.7% 6 2.1% GFP+ cells were ob-
served in mice injected with STAT12/2 TEL/JAK2-infected cells
(p < 0.001; Figure 7B, lower panels). This experiment was re-
peated using RAG22/2gc2/2 mice as recipients. In this setting,
no differences in disease latency or hematocrit values were de-
tected (Figure 7C), and the total amounts of erythroid precursors
(20.2% 6 4.7% and 21.7% 6 7.0% in regions P2–P5 for
STAT1+/2 and STAT12/2 cells, respectively; p = not significant)
and GFP+ cells (8.95%6 2.35% and 7.65%6 3.65% in regions
P2–P5 for STAT1+/2 and STAT12/2 cells, respectively; p = not
Figure 7. Low tumorigenicity of STAT1-deficient TEL/JAK2-induced MPD in
immunocompetent mice
Mean hematocrit values from peripheral blood of immunocompetent
(A) and immunodeficient (C) mice injected with TEL/JAK2-transduced
STAT1+/2or STAT12/2bone marrow cells and mice injected with PBS were an-
alyzed after 3 months (n = 10/genotype/cell amount). Data represent mean
6 SD. Flow-cytometric analysis of the erythroid compartment (CD71 and
TER119) in the spleens from one representative PBS-injected, one STAT1+/2-
injected, and one STAT12/2-injected immunocompetent (B) and immuno-
deficient (D) mouse (upper panel). Distribution of GFP+ cells in different
stages of erythroid development is indicated in the lower panel. E: Flow-cy-
tometric analysis of MHC class I expression and its mean fluorescence inten-
sity (MFI). MHC class I expression in the spleen of wild-type mice prior to infec-
tion with the TEL/JAK2 oncogene (left panels). Representative examples of
GFP+ erythroid precursor cells were isolated from spleens 3 months after
transplantation (right panels). Tumor editing is documented by the increase
in MHC class I expression, which is confined to the STAT12/2 cells and pro-
gressive with time (bottom row, panels labeled 12 and 15 weeks).84significant) in the spleens were comparable (Figure 7D). This ex-
periment rules out that the lack of STAT1 within the tumor cells
accounts for the differences observed in wild-type mice.
Again, in wild-type mice, the STAT12/2 GFP+ erythroid pre-
cursor cells expressed significantly higher MHC class I levels
compared to noninfected cells, indicating that the cells had
undergone an ‘‘editing’’ process (Figure 7E) as observed for
v-abl-induced B-lymphoid leukemia. The tumor editing of
MHC class I was first observed 3 months after injection of
STAT12/2 cells and was more pronounced 3 weeks thereafter
(Figure 7E, middle and right panels). Thus, this experiment faith-
fully recapitulated the observations made in v-abl-induced
B-lymphoid leukemia and confirms the hitherto unappreciated
tumor-promoting role of STAT1 in hematopoietic malignancies.
Discussion
The absence of STAT1 is generally thought to be detrimental be-
cause it allows for more rapid tumor progression (Badgwell
et al., 2004; Lee et al., 2000b; Lesinski et al., 2003; Nishibori
et al., 2004; Refaeli et al., 2002). Thus, the presence of STAT1
protects against tumor development, and therefore the mole-
cule is considered a tumor suppressor. The tumor-suppressing
effect of STAT1 is consistent with the in vitro effects on v-abl-
induced transformation; STAT12/2 cells gave rise to increased
numbers of growth factor-independent colonies. This observa-
tion is in strong contrast with leukemia development in the
mouse. We show here that the presence of STAT1 accelerates
leukemia progression in vivo. This paradox can only be under-
stood if immune surveillance is taken into account. Transformed
STAT12/2 cells were efficiently eliminated in immunodeficient
RAG22/2mice by NK cells. The role for NK cell-mediated tumor
surveillance was further substantiated in NK cell depletion
studies that abolished the differences between STAT12/2 and
STAT1+/2 leukemic cells and accelerated disease onset.
STAT12/2 mice were also more resistant to challenge with the
v-abl oncogene, succumbed to the disease with a decreased in-
cidence, and had an increased chance of survival. Moreover,
using models for leukemia and MPD, we documented that the
presence of STAT1 in a tumor was also detrimental in the con-
text of an intact immune system.
Our observations demonstrate that tumor progression and tu-
mor evolution can only be understood if the tumor is studied
within the context of an intact organism. It has been recently ap-
preciated that STAT1 supports expression of MHC class I mol-
ecules (Kamiya et al., 2004; Lee et al., 1999; Lieberman et al.,
2004). Quite predictably, we observed that loss of STAT1 re-
sulted in low expression ofMHCclass Imolecules. Several argu-
ments support the conclusion that there is a relation between
MHC class I levels on the tumor cells and their ability to evade
immunosurveillance by NK cells. (1) If MHC class I levels were
raised using a viral promoter, STAT1-deficient tumor cells
were rendered resistant to immunosurveillance. These cells
were not cleared by the innate immune system of RAG22/2
mice and gave rise to a leukemic disease that progressed al-
most as rapidly as that induced by STAT1-expressing cells.
This observation is consistent with the proposed model that
B-lymphoid malignancies are predominantly under surveillance
by NK cells (Cerwenka et al., 2000; Stoiber et al., 2004; Street
et al., 2004). (2) The natural course of the disease allowed for es-
cape of STAT1-deficient tumor cells from immunosurveillance.CANCER CELL JULY 2006
A R T I C L EThis escape was consistently accompanied by the upregulation
ofMHCclass I levels in all caseswhere injectedSTAT12/2 tumor
cells eventually gave rise to B-lymphoid leukemia and MPD. (3)
Finally, tumor evolution was associated with increased levels of
b2-microglobulin, the dimeric partner of MHC class I (Gobin
et al., 2003; Lee et al., 1999), and their common upstream reg-
ulator IRF-1 (Hobart et al., 1997). In all tumors that arose from
transformed STAT12/2 cells, their MHC class I levels substan-
tially exceeded those seen in the parental cell line and ap-
proached the levels observed in STAT1-expressing cells. Taken
together, these data are consistent with a model where high
MHC class I levels protect the tumor cells from elimination by
NK cells (Cerwenka and Lanier, 2001; Colucci et al., 2003; Karre
et al., 1986; Mocikat et al., 2003; Smyth et al., 2002).
When the concept of cancer immunoediting was originally in-
troduced, the focus was placed on the evolutionary arms race
between the tumor cell and the acquired immune system, that
is, T and B cells (Shankaran et al., 2001). Very recently, the the-
oretical framework was expanded by the observation that lym-
phomas are subject to immunosurveillance by the innate im-
mune system (Street et al., 2004). In the present work, we
demonstrate that the evolutionary pressure exerted by NK cells
sculpts and edits the leukemic tumor cells in a predictable man-
ner. Under these conditions, upregulation of MHC class I mole-
cules is the mechanism that allows for escape (Cerwenka and
Lanier, 2001; Colucci et al., 2003; Karre et al., 1986; Mocikat
et al., 2003; Smyth et al., 2002). Accordingly, in immunocompe-
tent and immunodeficient mice, STAT1-expressing tumor cells
gave rise to highly aggressive disease because they could not
be cleared by NK cells. Likewise, the evolutionary arms race
was readily evident, if STAT1-deficient tumor cells were in-
jected: the tumor cells eventually overcame their defect by by-
passing the STAT1-dependent regulation of MHC class I. This
upregulation was stable—as seen by the fact that STAT12/2
tumors maintained high MHC class I levels after long cultivation
periods (ex vivo)—and resulted in a concerted upregulation of
b2-microglobulin and IRF-1. Thus, the mechanistic possibilities
of a STAT1-independent regulation of MHC class I are diverse
and may exceed a simple gain-of-function mutation.
Phenotypically, the disease inflicted by transplantingSTAT12/2
v-abl-transformedcells into immunodeficientmicewas similar to
that induced in STAT1-deficient animals. The same effect was
alsoobserved indiseasephenotypescausedby transplantingei-
ther STAT12/2 leukemia or STAT12/2 MPD in immunocompe-
tent hosts. In other words, irrespective of the model system
used, STAT12/2 transformed cells either were easily rejected,
had increased latencies, developedmoremoderate formsofma-
lignancies, or gave rise to tumors only after acquiring an ‘‘edited’’
phenotype,whichmanifested itself in an increase ofMHCclass I.
The concept of cancer immunoediting is based on the follow-
ing predictions: the tumor can be eliminated by the immune sys-
tem, and the tumor cells are sculpted by the immune system and
may escape by Darwinian evolution. Our study verifies the pre-
dictions of this concept, supporting its general applicability. The
role of IFN-g and its signaling component STAT1, however, has
to be reevaluated. While IFN-g acts like a potent tumor suppres-
sor, this role cannot be generally attributed to STAT1. In fact, the
phenotypes observed in IFN-g- and STAT1-deficient mice are
diametrically opposed.
MHC class I-mediated killing by NK cells has been extensively
investigated in various tumors. This concept is therefore wellCANCER CELL JULY 2006documented and understood in considerable detail. Hence,
there is substantial circumstantial evidence from this earlier
work that is in line with our model that STAT1 acts as a tumor
promoter in leukemia and MPDs or, conversely, that a lack of
STAT1 and low MHC class I expression protects the organism
from hematopoietic malignancies. In light of this finding, our
work may provide the basis for novel therapeutic approaches,
using concerted inhibition of STAT1 and MHC class I.
Experimental procedures
Animals
BALB/cJ (BALB/c) STAT12/2 mice, C57BL/6J (C57BL/6) IFN-g2/2 mice,
RAG22/2mice,RAG22/2gc2/2mice, andwild-type BALB/cmiceweremain-
tained at the Biomedical Research Institute, Medical University of Vienna,
Research Institute of Molecular Pathology, IMP, Vienna. All animal experi-
ments were carried out in accordance with protocols approved by the Animal
Welfare Committee and with the general regulations specified by the Good
Scientific Practices guidelines of the Medical University of Vienna.
Mouse experiments
Each transplantation experiment was repeated at least in an additional inde-
pendent experiment, and the observations were consistently reproducible. In
detail, cells from six independently derived STAT1+/2 and six STAT12/2 cell
lines were injected into RAG22/2 mice (n = 40 in total) and RAG22/2gc2/2
mice (n = 10 in total). For MHC class I (H-2Dd) reconstitution, STAT12/2 (pa-
rental cell line),STAT12/2 +H2Dd, and STAT1+/2 (parental cell line) cells were
injected into RAG22/2mice (n = 18 in total), STAT12/2mice (n = 18 in total),
and wild-type BALB/c mice (n = 18 in total). For transplantation into immuno-
competent mice, STAT1+/2 and STAT12/2 leukemic cell lines were injected
at different cell numbers (33 106 and 33 105) into syngeneic BALB/c recip-
ients (n = 60 in total). For TEL/JAK2-induced experiments, bonemarrow from
STAT1+/2 and STAT12/2 mice was transduced with pMSCV-TEL/JAK2-
IRES-GFP-derived retrovirus and cultured as described earlier (Moriggl
et al., 2005) prior to injection into syngeneic BALB/c mice (n = 20 in total)
or RAG22/2gc2/2 mice (n = 12 in total). For NK depletion experiments,
wild-type BALB/c mice (n = 8 in total) were treated (i.p.) with a-asialo GM1
(WAKO, Japan) on days 24, 0, and 7 of tumor cell injection. For short-term
homing experiments CFSE-labeled STAT1+/2 and STAT12/2 cell lines were
injected into wild-type (n = 8) or RAG22/2 mice (n = 8) and analyzed 4 days
after injection. For newborn infection experiments, mice were injected
intraperitoneally with 50 ml of replication incompetent ecotropic retrovirus
encoding for v-abl.
Flow cytometry
Single-cell suspensions were preincubated with aCD16/CD32 antibodies
(BD/Pharmingen) to prevent nonspecific Fc receptor-mediated binding. Cells
(5 3 105) were stained with monoclonal antibodies conjugated with fluores-
cent markers and analyzed on FACScan and FACScanto (Beckton-Dickin-
son) with CellQuestPro and Facs Diva software. The antibodies used for lin-
eage determination included the B cell lineage markers B220 (RA3-6B2),
CD19 (1D3), and CD43 (1B11); the T cell marker CD3 (17A2); the pan-NK
marker (DX5); and the erythroid lineage markers CD71 (C2) and TER119
(Ter119) (all BD/Pharmingen). In addition, an antibody against MHC class I
(H-2Dd, clone 34-5-8S, BD/Pharmingen) was used. For cell cycle analysis,
the cells were fixed in a buffer containing 0.05 mg/ml propidium iodide,
0.01% Triton X-100, and 0.1% sodium citrate.
Cytotoxicity assay
The YAC-1 cell line and fetal liver-derived STAT1+/2, STAT12/2, and
STAT12/2 + H-2Dd cell lines as well as tumor-derived STAT12/2 MHC Ihigh
cells were used as target cells. DX5+ purified splenocytes were used as
effector cells after 10 days of culture in h-IL-2 (5000 U/ml). Lactate dehydro-
genase (LDH) release was measured as described using the CytoTox 96
Non-Radioactive Cytotoxicity Assay (Promega).
Statistical analysis
Statistics were carried out using Student’s t test and the c2 test as appropri-
ate. Kaplan-Meier plots were analyzed for statistical significance using the85
A R T I C L Elog-rank test. Cytotoxicity assays were analyzed by the ANOVA test with
Tukey’s post hoc test for every E/T ratio.
Additional information regarding analysis of mice, RT-PCRs, tissue culture
conditions, transformation, and proliferation assays is available within the
Supplemental Data.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/1/77/DC1/.
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